收费全文 | 64429篇 |
免费 | 5361篇 |
国内免费 | 4497篇 |
耳鼻咽喉 | 392篇 |
儿科学 | 1786篇 |
妇产科学 | 848篇 |
基础医学 | 12282篇 |
口腔科学 | 1301篇 |
临床医学 | 5690篇 |
内科学 | 9809篇 |
皮肤病学 | 932篇 |
神经病学 | 4025篇 |
特种医学 | 1377篇 |
外国民族医学 | 31篇 |
外科学 | 3347篇 |
综合类 | 13752篇 |
现状与发展 | 25篇 |
一般理论 | 1篇 |
预防医学 | 3281篇 |
眼科学 | 1143篇 |
药学 | 5021篇 |
6篇 | |
中国医学 | 1439篇 |
肿瘤学 | 7799篇 |
2024年 | 52篇 |
2023年 | 618篇 |
2022年 | 987篇 |
2021年 | 1914篇 |
2020年 | 1719篇 |
2019年 | 1648篇 |
2018年 | 1568篇 |
2017年 | 1771篇 |
2016年 | 2071篇 |
2015年 | 2105篇 |
2014年 | 3222篇 |
2013年 | 4307篇 |
2012年 | 3504篇 |
2011年 | 4276篇 |
2010年 | 3483篇 |
2009年 | 3542篇 |
2008年 | 3812篇 |
2007年 | 4189篇 |
2006年 | 4044篇 |
2005年 | 3779篇 |
2004年 | 3430篇 |
2003年 | 2982篇 |
2002年 | 2636篇 |
2001年 | 2409篇 |
2000年 | 1984篇 |
1999年 | 1688篇 |
1998年 | 1457篇 |
1997年 | 1213篇 |
1996年 | 760篇 |
1995年 | 777篇 |
1994年 | 574篇 |
1993年 | 394篇 |
1992年 | 299篇 |
1991年 | 238篇 |
1990年 | 210篇 |
1989年 | 138篇 |
1988年 | 97篇 |
1987年 | 71篇 |
1986年 | 56篇 |
1985年 | 85篇 |
1984年 | 48篇 |
1983年 | 21篇 |
1982年 | 35篇 |
1981年 | 26篇 |
1980年 | 15篇 |
1979年 | 12篇 |
1978年 | 6篇 |
1977年 | 6篇 |
1976年 | 3篇 |
1975年 | 2篇 |
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献Methods and Results: This case-control association study contained 1673 samples, including 869 ophthalmic patients and 804 controls. Twelve tag SNPs have been selected from the MYP10 and MYP15 loci and genotyped by SNaPshot method. Among 12 SNPs, rs4840437 and rs6989782 in TNKS gene were found significant association with HM. Carriers of rs4840437G allele and rs4840437GG genotype created a low risk of high myopia (P = .036, OR = 0.81, 95%CI = 0.71–0.93; P = .016, OR = 0.73, 95%CI = 0.56–0.96; respectively). Carriers of rs6989782T allele and rs6989782TT+CT genotype also had a decreased risk of high myopia (P = .048, OR = 0.82, 95%CI = 0.71–0.94; P = .006, OR = 0.74, 95%CI = 0.59–0.92; respectively). Other 10 SNPs displaced nonsignificant association with HM. Additionally, the risk haplotype AC and the protective haplotype GT, generated by two SNPs in TNKS, were considerably more likely to be association with HM (for AC, P = .002 and OR = 1.26; for GT, P = .027 and OR = 0.84).
Conclusions: Our results demonstrated that some heritable variants in the TNKS gene are associated with HM in the Han population. The possible functions of TNKS in the development and pathogenesis of hereditary high myopia still require further researches to identify. 相似文献